COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

52 results for "Cancer" and "Endocrine Cancers"

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

A Phase 1/2a, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of PEN-866 in patients with advanced solid malignancies
Protocol No
TARVEDA-PEN-866-001-REFMAL492
Sub Category
Breast Cancers, Thoracic Cancers, Sarcoma, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Protocol No
JOUNCE-JTX-8064-101
Sub Category
Brain and Spine Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers

A Randomized Phase II Trial Of Triplet Therapy (A Pd-L1 Inhibitor Durvalumab (Medi4736) In Combination With Olaparib And Cediranib) Compared To Olaparib And Cediranib Or Durvalumab (Medi4736) And Cediranib Or Standard Of Care Chemotherapy In Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Or Fallopian Cancer Who Have Received Prior Bevacizumab

We are doing this study because we want to find out if these drug combinations are better or worse than the usual approach for your recurrent, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The usual approach is defined as care most people get for your cancer
Protocol No
NRG-GY023
Sub Category
Gynecologic Cancers

Molecular Analysis for Therapy Choice (MATCH)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Protocol No
ECOG-EAY131-MATCH
Sub Category
Brain and Spine Cancers, Early Phase/Multiple Disease Site Cancers, Hematologic/Blood Related Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers

Optimizing NeuroCOgnition with Whole Brain Radiation Therapy (WBRT) using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole Brain Radiation Therapy for Brain Metastases

This project is being done to test a new technique called pulsed reduced dose-rate
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
Protocol No
IIT-SAEED-ONCO-RT
Sub Category
Brain and Spine Cancers

A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors

A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Protocol No
IIT-MENON-COINCIDE
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers

A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation

To investigate how HB-201 affects the immune response
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
Protocol No
HOOKIPA-H-200-002
Sub Category
Gynecologic Cancers, Head and Neck Cancers

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
Sub Category
Brain and Spine Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL

This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Sub Category
Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Prostate and Urologic Cancers, Gastrointestinal Cancers, Head and Neck Cancers